【摘要】 目的探讨替格瑞洛治疗急性冠脉综合征的临床价值。方法选取自2015年1月至2016年1月收治的120例急性冠脉综合征患者为研究对象,采用随机数字表法分为A组与B组,每组各60例。A组患者给予氯吡格雷+阿司匹林治疗,B组患者给予替格瑞洛+阿司匹林治疗。比较两组患者治疗有效率、血浆黏度、全血黏度、血小板聚集率、主要不良心脑血管事件发生情况以及并发症发生情况。结果 B组患者治疗总有效率为93. 3%(56/60),显著高于A组的81. 7%(49/60),差异有统计学意义(P <0. 05)。治疗后,两组患者血浆黏度、全血黏度及血小板聚集率均较治疗前明显降低,且B组患者上述指标均低于A组,差异均有统计学意义(P <0. 05)。B组患者主要不良心脑血管事件发生率为11. 7%(7/60),显著低于A组的31. 7%(19/60),差异有统计学意义(P <0. 05)。两组患者均未出现重度出血。A组患者出血4例,呼吸困难1例,并发症发生率为8. 3%(5/60); B组患者出血6例,呼吸困难1例,并发症发生率为11. 7%(7/60)。两组患者并发症发生率比较,差异无统计学意义(P> 0. 05)。结论替格瑞洛治疗急性冠脉综合征疗效显著,能有效降低主要不良心脑血管事件发生率,安全性高。更多还原

【Abstract】 Objective To investigate the clinical value of Ticagrelor in the treatment of acute coronary syndrome( ACS). Methods A retrospective study was performed on 120 cases of patients with ACS who were admitted from January 2015 to January 2016. Patients were randomly divided into the Group A and Group B,with 60 cases in each group. Patients in the Group A were given Clopidogrel combined with asprin,the others in the Group B were given Ticagrelor combined with asprin. The effective rate,plasma viscosity,whole blood viscosity,platelet aggregation rate,adverse cardiovascular events and complications were compared between the two groups. Results The total effective rate of the Group B was 93. 3%( 56/60),which was significantly higher than 81. 7%( 49/60) of the Group A( P < 0. 05). After treatment,plasma viscosity,whole blood viscosity and platelet aggregation rate of the two groups were significantly lower than those before treatment,and the above indexes of the patients in Group B were lower than those in Group A( P < 0. 05). The incidence of adverse cardiovascular events in Group B was 11. 7%( 7/60),significantly lower than 31. 7%( 19/60) in Group A( P <0. 05). No severe bleeding occurred in either group. In Group A,there were 4 cases of bleeding and 1 case of dyspnea,and the complication rate was 8. 3%( 5/60). Six patients in Group B had bleeding and one had dyspnea,and the incidence of complications was11. 7%( 7/60). There was no significant difference in the incidence of complications between the two groups( P > 0. 05).Conclusion Ticagrelor is effective in the treatment of acute coronary syndrome,which can effectively reduce the incidence of adverse cardiovascular events with high safety.更多还原